Telix Executive and Leadership Team

Kevin Richardson, the Chief Executive Officer (Americas) at Telix, directs all commercial operations across the North American market. Richardson manages the expansion of the Illuccix product portfolio while ensuring regulatory compliance with FDA standards. By overseeing regional sales teams and distribution networks, the Chief Executive Officer (Americas) drives market penetration for prostate cancer imaging agents. This leadership role involves constant collaboration with global stakeholders to align regional growth with the broader corporate mission of advancing theranostics. Kevin Richardson maintains focus on scaling infrastructure to meet rising clinical demand for molecularly targeted radiation. Through strategic planning and operational oversight, the Chief Executive Officer (Americas) secures a competitive position for the company within the complex biopharmaceutical landscape. Richardson optimizes resource allocation to support long-term commercial success and patient access across the Americas.

Michael Didocha, the Chief Financial Officer (Americas) at Telix, manages the financial health and fiscal strategy for regional operations. Didocha oversees capital allocation, budgeting, and financial reporting to ensure alignment with Nasdaq listing requirements. By analyzing market trends and revenue streams from Illuccix, the Chief Financial Officer (Americas) supports informed decision-making for the executive team. This role involves mitigating financial risks while identifying opportunities for investment in clinical trials and commercial expansion. Michael Didocha drives fiscal discipline across all departments to maximize shareholder value. Through precise financial modeling and cost management, the Chief Financial Officer (Americas) provides the necessary resources for scaling operations in the competitive biopharmaceutical sector. Didocha maintains transparency with investors and stakeholders, ensuring the company possesses the liquidity required to advance the pipeline of diagnostic and therapeutic radiopharmaceuticals across the North American region.

Darren Patti, the Group Chief Operating Officer at Telix, executes the global operational strategy to streamline the commercialization of theranostic products. Patti oversees supply chain logistics, manufacturing efficiency, and cross-functional workflows to ensure consistent product delivery. By coordinating international operations, the Group Chief Operating Officer aligns internal processes with the company's mission to improve cancer treatment outcomes. This role involves optimizing the production of radiopharmaceuticals to meet global regulatory standards and clinical demand. Darren Patti drives operational excellence by implementing scalable systems that support the rapid growth of the oncology pipeline. Through continuous process improvement, the Group Chief Operating Officer enhances organizational agility and responsiveness to market shifts. Patti manages the integration of new technologies into the manufacturing framework, ensuring the company maintains a robust and reliable supply chain for diagnostic and therapeutic agents worldwide.

Paul Schaffer, the Chief Technology Officer at Telix, architects the technical roadmap for next-generation radiopharmaceutical development. Schaffer oversees the integration of molecularly targeted radiation technologies into the existing product pipeline. By managing research and development initiatives, the Chief Technology Officer ensures the company remains at the forefront of theranostic innovation. This role involves bridging the gap between laboratory discovery and commercial-scale manufacturing processes. Paul Schaffer drives technical excellence by evaluating emerging imaging agents and therapeutic compounds for urologic and neuro-oncology applications. Through rigorous scientific oversight, the Chief Technology Officer maintains the integrity of the product portfolio while navigating complex regulatory requirements. Schaffer fosters collaboration with engineering teams to refine production methodologies, ultimately enhancing the efficacy and safety of diagnostic tools. The Chief Technology Officer secures the technological foundation necessary for sustained growth in the global oncology market.

David Cade, the Chief Medical Officer at Telix, directs the clinical development and medical strategy for the entire radiopharmaceutical portfolio. Cade oversees the design and execution of clinical trials for urologic, neuro, and musculoskeletal oncology programs. By evaluating clinical data and safety profiles, the Chief Medical Officer ensures that all therapeutic and diagnostic agents meet rigorous medical standards. This role involves engaging with global health authorities to secure regulatory approvals for new theranostic applications. David Cade drives the medical vision by translating scientific research into actionable clinical solutions for cancer patients. Through collaboration with the research and development teams, the Chief Medical Officer validates the efficacy of molecularly targeted radiation. Cade maintains high standards of medical integrity, ensuring that the company's pipeline addresses critical unmet needs in oncology while supporting the broader goal of advancing precision medicine on a global scale.